Connect with us

Best Biotech Penny Stocks to Buy Now? 3 to Watch in January

Check these three biotech penny stocks out for your watchlist right now
The post Best Biotech Penny Stocks to Buy Now? 3 to Watch in January appeared first on Penny Stocks to Buy, Picks, News and Information |



3 Biotech Penny Stocks to Watch in January 2022 

With the second full day of trading penny stocks and blue chips in 2022 here, there are plenty of things that investors need to know. After yesterday’s large positive momentum with Tesla Inc. (NASDAQ: TSLA) climbing over 10%, many investors are bullish about both the near and far-term in the stock market. 

While it is hard to say what will happen with biotech penny stocks due to the pandemic still going on, many hope that the Omicron variant could signal the end once case numbers begin to drop off. With biotech penny stocks and penny stocks in general, it is crucial to have a thorough understanding of how the market is moving and how to take advantage. Because small-caps are so speculative, were often see large volatile moves during intraday or intra week trading. Additionally, most investors tend to swing trade penny stocks. 

[Read More] Metaverse Penny Stocks To Watch As Traders Look To Buy New Tech

This means that movement is desired and can be used to make money. But, without the proper information by your side and a consistent trading strategy, making money with penny stocks will be extremely difficult. So as we barrel further into 2022, there may be a lot to keep track of. But, if we can stay up to date with all the news related to the companies we’re interested in, it can be much easier than previously imagined. Considering this, let’s take a look at three penny stocks to watch in January 2022. 

3 Biotech Penny Stocks For Your January Watchlist 

  1. Hoth Therapeutics Inc. (NASDAQ: HOTH
  2. Plus Therapeutics Inc. (NASDAQ: PSTV
  3. Immix Biopharma Inc. (NASDAQ: IMMX

Hoth Therapeutics Inc. (NASDAQ: HOTH)

One of the largest premarket gainers so far is HOTH stock, pushing up by over 51%. While many large gains with penny stocks can occur with no news, HOTH made an exciting announcement during premarket trading today. The company stated that it has generated proof-of-concept data for its Alzheimer’s drug known as HT-ALZ. 

“The overall positive result from these studies is a first step but a big one in the development of HT-ALZ as an Alzheimer’s therapeutic. HT-ALZ is a unique therapeutic in the AD development space because it is eligible for streamlined development under the 505(b)(2) pathway, including available safety data. This allows Hoth to reach efficacy clinical trials faster and bring a new potential treatment for patients with Alzheimer’s disease.”

The Chief Scientific Officer of Hoth Therapeutics, Stefanie Johns

This is big news for the company and adds another layer to its already sizable pipeline. Outside of this, the company works on next-gen therapies for unmet medical needs. This includes those used in treating atopic dermatitis, chronic wounds, pneumonia, and more recently, Covid-19. So, as a popular company with a lot going on right now, it looks like HOTH stock could be worth adding to your list of penny stocks to watch. 

Plus Therapeutics Inc. (NASDAQ: PSTV) 

Another major gainer during premarket trading today is PSTV stock. By market open, shares of PSTV stock had shot up by a staggering 75%. While shares of PSTV are still down by around 47% in the past twelve months, this major bullish turnaround is encouraging to say the least.

[Read More] Are These Penny Stocks on Your January 2022 List?

Today, the company announced two milestones for the cGMP manufacturing of its Rhenium-186 NanoLiposome product. The company states that it has entered into a master services agreement with IsoTherapeutics Group LLC to develop, manufacture and supply this compound for use in an investigational radiotherapeutic. 

“These are important steps towards our goal to confirm fully compliant 186RNL available by mid-2022 for our ongoing clinical trials in adults with recurrent glioblastoma, leptomeningeal metastases and other life cycle management trials.

We are delighted to develop a strong, effective collaboration with IsoTherapeutics, a company with extensive capabilities in radiopharmaceuticals technology and development. Their demonstrated expertise is precisely what we are looking for in a manufacturing partner.” 

The CEO of Plus Therapeutics, Marc Hedrick, M.D.

This is big news for the company and highlights its continued desire to grow in the biotech and cancer industries respectively. With that in mind, will PSTV be on your penny stocks watchlist this month?


Immix Biopharma Inc. (NASDAQ: IMMX) 

While IMMX stock is technically no longer a penny stock at over $7.50, just a few days ago, shares were well under the $4 mark. As a result of this, in the past five days, IMMX stock has gained a sizable 81% in value. 

One of, if not the main reason for this comes as the company announced the FDA had granted it a Rare Pediatric Disease designation for IMX-110. For those unfamiliar, IMX-110 has indications in treating cancer in children, specifically rhabdomyosarcoma, which affects around 200,000 in the U.S. It’s worth noting that this exciting news comes around a month after the company IPO’d on the NASDAQ market. Since then, we have witnessed a sizable climb with IMMX stock as mentioned above. 

Aside from this, the company is working on its proprietary System Multi-Action RegulaTors SMARxT Tissue-Specific Platform. This allows drugs to accumulate at intended sites at a rate of almost 5 times faster than traditional medicine delivery platforms. So, with the major focus on biotech penny stocks right now, IMMX could be worth keeping an eye on. And while it may not be a penny stock for long, there’s no doubt that IMMX stock is making a large headway on the industry right now. 


Which Biotech Penny Stocks Are You Watching Right Now?

As a whole, the biotech industry has remained very popular over the last two years. Because of this, investors continue to search for the best biotech penny stocks to buy. Now, this can and will be challenging without the right information by your side. 

[Read More] 4 Penny Stocks To Buy For Under $5 With High Short Interest

So for that reason, knowing exactly what is going on with the companies you’re interested in, is crucial to your trading strategy. Right now, there is quite a large amount of volatility. And, it is likely that these large market fluctuations will only continue to occur over the next year. With all of this in mind, which biotech penny stocks are you watching right now?

If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!

The post Best Biotech Penny Stocks to Buy Now? 3 to Watch in January appeared first on Penny Stocks to Buy, Picks, News and Information |

Read More

Continue Reading


Treasury Market Plays Catch-Up With Higher-For-Longer Risk

The collective wisdom of the bond market for much of this year has been betting that interest rates would soon peak and fall. But those bets appear to…



The collective wisdom of the bond market for much of this year has been betting that interest rates would soon peak and fall. But those bets appear to be unwinding in the wake of Wednesday’s Federal Reserve meeting and press conference.

Exhibit A is the rise in the 2- and 10-year Treasury yields, which are widely followed as key maturities for economic and financial markets analytics. On those fronts the crowd is reassessing its recent view that rate cuts are on the near-term horizon.

Let’s start with the 2-year Treasury yield, which is considered a proxy for market expectations on Fed policy. For much of this year the 2-year yield has traded below the effective Fed funds rate, which implies that the market expects the central bank’s rate hike will peak and perhaps reverse. But that view appears to be fading as the 2-year yield moves closer to the current 5.25%-to-5.50% Fed funds rate range.

The 10-year yield is pushing higher again too. In yesterday’s trading (Sep. 21), the benchmark rate rose to 4.49%, the highest since 2007.

Inflation-indexed Treasury yields continue to push higher too, testing the 2%-plus real range.

One of the catalysts that’s reportedly behind the latest run of higher Treasury yields is Fed Chair Powell’s hawkish comments on Wednesday on the matter of real (inflation-adjusted) interest rates.

“It’s a real rate that will matter and that needs to be sufficiently restrictive,” he advised, although exactly what level defines “restrictive” was left unsaid. “I would say you know it’s sufficiently restrictive only when you see it,” he added. “It’s not something you can arrive at with confidence in a model or in various estimates.”

By some accounts, the Fed appears to be on a path to leave rates higher for longer. Fed rate hikes may be over, or perhaps there’s one more in the pipeline, but rate cuts are expected to come later than recently expected.

As The Wall Street Journal reports:

“The fact that we’ve come this far lets us really proceed carefully,” said Powell. He used those words—“proceed carefully”—six times during Wednesday’s news conference, a sign of heightened caution about lifting rates.

“He didn’t sound to me like he was itching to hike again,” said Michael Feroli, chief U.S. economist at JPMorgan Chase, who thinks the Fed’s July rate rise will be its last for the current cycle. “For Powell, he sounds like he’s pretty comfortable where they are, sitting back, and watching things play out,” Feroli said.

The new dot plots for the Fed – the FOMC participants expectations for the Fed funds rate – supports the case for a higher for longer outlook. The FT notes:

The median estimate of the Fed’s 19 policymakers is for the bank’s benchmark rate to fall to just 5 per cent to 5.25 per cent next year. That was significantly higher than the 4.5 per cent to 4.75 per cent they signaled when the dot plot was last updated in June. By 2026, it was still forecast to be between 2.75 per cent and 3 per cent.

“What they’re saying there is if you have stronger growth for this year and next, it increases the risk that core inflation does not descend as much as they hope and expect,” said Daleep Singh, an ex-New York Fed official who is now chief global economist at PGIM Fixed Income.

“Therefore there is a potential need to keep nominal interest rates somewhat higher than they previously forecast,” he added.

The good news for investors is that the highest yields in ~15 years, either real or nominal, can be locked in with a buy-and-hold strategy. No one knows if current rates are at or near a peak, but this much is clear: the case for a relatively higher allocation to Treasuries vs. recent history hasn’t looked this compelling since George W. Bush was walking the floor in the Oval Office.

Learn To Use R For Portfolio Analysis
Quantitative Investment Portfolio Analytics In R:
An Introduction To R For Modeling Portfolio Risk and Return

By James Picerno

Read More

Continue Reading


Bitcoin mining can help reduce up to 8% of global emissions: Report

The report highlighted that Bitcoin mining can convert wasted methane emissions into less harmful emissions.
A paper published by the…



The report highlighted that Bitcoin mining can convert wasted methane emissions into less harmful emissions.

A paper published by the Institute of Risk Management (IRM) concluded that Bitcoin (BTC) has the potential to be a catalyst for a global energy transition. 

IRM Energy and Renewables Group members Dylan Campbell and Alexander Larsen published a report titled “Bitcoin and the Energy Transition: From Risk to Opportunity.” The paper argued that while BTC was perceived as a risk because of its energy consumption, it can also catalyze energy transition and lead to new solutions for energy challenges worldwide.

Within the report, the authors also highlighted the important function of energy and the increasing need for reliable, clean and more affordable energy sources. Despite the criticisms of Bitcoin’s energy intensity, the study provided a more balanced view of Bitcoin by showing the potential benefits BTC can bring to the energy industry.

Amount of vented methane that can be used in Bitcoin mining. Source: IRM

According to the report, Bitcoin mining can reduce global emissions by up to 8% by 2030. This can be done by converting the world’s wasted methane emissions into less harmful emissions. The report cited a theoretical case saying that using captured methane to power Bitcoin mining operations can reduce the amount of methane vented into the atmosphere. 

Related: Bitcoin energy pivot achieves what ‘few industries can claim’ — Bloomberg analyst

The paper also presented other opportunities for Bitcoin to contribute to the energy sector. According to the report, Bitcoin can contribute to energy efficiency through electricity grid management by using Bitcoin miners and transferring heat from miners to greenhouses.

“We have shown that while Bitcoin is a consumer of electricity, this does not translate to it being a high emitter of carbon dioxide and other atmospheric pollutants. Bitcoin can be the catalyst to a cleaner, more energy-abundant future for all,” the authors wrote.

Magazine: How to protect your crypto in a volatile market: Bitcoin OGs and experts weigh in

Read More

Continue Reading


GBP/USD extends losses on mixed UK data

UK retail sales improve, PMIs remain in contraction The British pound is in negative territory after two days of losses. In the European session, GBP/USD…



  • UK retail sales improve, PMIs remain in contraction

The British pound is in negative territory after two days of losses. In the European session, GBP/USD is trading at 1.2245, down 0.40%. The struggling pound is down 1.1% this week and is trading at its lowest levels since late March.

UK retail sales improve, PMIs mixed

It is a busy day on the data calendar for UK releases. Retail sales rose in August by 0.4% m/m, following a 1.1% decline in July and was just shy of the market consensus of 0.5%. The sharp decline in July was largely due to unusually wet weather. On an annual basis, retail sales fell by 1.4%, compared to -3.1% in July. Consumer spending has been in a nasty rut, as annualized retail sales have now declined for 17 straight months. The silver lining was that the -1.4% drop marked the slowest pace of contraction in the current streak.

The September PMIs were a mixed bag. The Services PMI slowed to 47.2 in September, down from 49.5 in August and missing the consensus estimate of 49.2. This marked a second straight deceleration and the sharpest contraction since January 2021. The Manufacturing PMI increased to 44.2 in September, up from 43.0 in August and above the consensus estimate of 43.0.

The decline in activity in both services and manufacturing points to a UK economy that continues to cool. The Bank of England, which held interest rates on Thursday, will be hoping that the slowdown translates into lower inflation and that it can continue to hold interest rates.

UK consumer confidence remains low, but there was a bit of an improvement in September. The GfK consumer confidence index rose to -21, up from -25 in August and beating the consensus estimate of -27. This was the highest reading since January 2022, but the economy has a long way to go before consumers show optimism about the economic outlook.


GBP/USD Technical

  • GBP/USD is testing support at 1.2267. The next support level is 1.2156
  • There is resistance at 1.2325 and 1.2436

Read More

Continue Reading